In the complex, high-stakes world of cardiothoracic medicine, few procedures carry the weight and promise of a lung transplant. It is the ultimate restorative measure for patients with end-stage respiratory failure, a clinical "last resort" that offers the gift of time. Yet, as medical technology leaps forward, the systemic framework supporting these patients across Europe remains fragmented.
Dr. Vicky Gerovasili, a consultant lung transplant physician and co-director of the cardiothoracic transplant programme at Harefield Hospital in London, sits at the nexus of this evolution. For Dr. Gerovasili, the practice is not merely about the surgery itself—it is about the lifelong, intricate relationship built between a specialist team and the 500-plus transplant recipients under their care. In a recent dialogue, she shed light on the paradigm shifts, persistent inequalities, and the urgent need for a unified European strategy in transplant care.
The Evolution of a Lifesaving Discipline
To understand the current state of transplantation, one must look at the seismic shifts that have occurred in just the last decade. The field is in a constant state of flux, driven by pharmacological breakthroughs that have fundamentally altered the patient demographic.
"The biggest breakthrough in my career has undoubtedly been the effect of new drugs for patients living with cystic fibrosis," Dr. Gerovasili explains. The introduction of CFTR modulators has been transformative; these therapies have proven so effective that a significant majority of patients who once would have been prime candidates for a lung transplant now see their condition stabilized without the need for surgery.
However, this success story masks a persistent, sobering reality: there remains a population of patients for whom no pharmaceutical intervention is enough. These individuals face the harsh lottery of donor availability. Despite the scientific advancement, the clinical demand continues to outpace the supply of donor organs, leaving many patients waiting for a phone call that may never come.
Chronology of Change: From Surgery to Advocacy
The history of lung transplantation is often viewed through the lens of surgical technicality—the first successful procedures, the refinements in immunosuppression, and the improvements in post-operative survival. But according to Dr. Gerovasili, the most significant shift in the modern era is cultural rather than technical.
"Another change has been the patient voice, which has increasingly become stronger," she notes. "As clinicians, we are becoming better at listening to their experiences and priorities."
This shift has moved the medical community away from a paternalistic model of care toward a collaborative partnership. This evolution is now reaching a critical point through the work of the European Lung Foundation (ELF) and the European Respiratory Society (ERS) Transplantation Working Group. This group is currently spearheading a landmark initiative: the first European-level survey of its kind, co-developed by patients and clinicians to capture the lived experience of transplant recipients.
Supporting Data and the "Inequality Gap"
While the clinical success of transplants is celebrated, the systemic health data surrounding these procedures reveals a fragmented map of Europe. The primary challenge, Dr. Gerovasili argues, is a profound lack of granular data.
Currently, most European nations report only the most basic metrics: the total number of transplants performed and, in some cases, short-term survival statistics. This is insufficient for measuring true quality of care.
"We know that access to lung transplantation varies greatly across countries and regions," Dr. Gerovasili explains. "Certain groups of patients are particularly disadvantaged, depending on where they live, their background, or their socioeconomic status."
The "inequality gap" is not just about who gets the surgery; it is about the long-term support infrastructure that follows. When a patient leaves the hospital, their journey is far from over. They require highly specialized, lifelong monitoring. Yet, there is currently no standardized, Europe-wide framework to ensure that a patient in one country receives the same quality of post-transplant care as a patient in another. The lack of standardized patient-reported outcome measures (PROMs) means that the medical community is essentially flying blind regarding the actual quality of life and long-term health trajectories of these patients.
Official Perspectives: The Need for a Unified Platform
The collaboration between the ERS and the ELF is designed to address this data vacuum. By engaging patients directly, the current survey aims to map how transplant centers operate across different health systems.
Dr. Gerovasili sees this as a foundational step. "A first step is to map how transplant centres work across different regions and health systems," she says. "This would help us understand variation and learn from good practice. I would welcome a European initiative that enables transplant centres to share knowledge and improve long-term care beyond survival alone."
The vision for the future is a digital, Europe-wide platform that facilitates real-time communication between transplant centers. Such a platform would serve as a hub for innovation, allowing for large-scale research that reflects the vast diversity of the European patient population. By pooling data and expertise, European clinicians could move beyond regional silos and establish a continent-wide "gold standard" for care.
The Societal Implications of Transplantation
Perhaps the most compelling argument for reforming the current system is the profound societal return on investment that transplantation offers. It is a common misconception that a transplant is the end of a patient’s active life; in reality, for most, it is a restoration of agency.
"Lung transplantation transforms lives," Dr. Gerovasili emphasizes. "Evidence shows that more than half of transplant recipients return to work a year after their transplant. This benefits not only patients and their families, but also society more broadly."
The implications are clear: a transplant recipient who returns to the workforce, engages with their community, and maintains their health is a testament to the success of the system. However, this success is contingent upon high-quality, long-term specialized care. If the system fails to support the recipient in the years following the surgery, that transformative potential is lost.
A Call to Action for Policymakers
The message to policymakers is unequivocal: the current, fragmented approach to transplant care is a missed opportunity. There is a moral and economic imperative to standardize the quality of care across borders.
The responsibilities of the medical community and the state are twofold. First, they must recognize that lung transplantation is not a "quick fix" but a commitment to a lifelong, complex medical relationship. Second, they must invest in the infrastructure—the data registries, the communication platforms, and the specialized follow-up networks—required to ensure that every patient, regardless of their geography, has access to the best possible outcomes.
As the ELF/ERS survey begins to collect data, it serves as a wake-up call for the European healthcare landscape. The "patient voice," once an afterthought, is now driving the agenda. The future of transplantation will not be defined solely by the surgeon’s scalpel, but by the strength of the network that supports the patient long after the stitches have healed.
How You Can Get Involved
The European Lung Foundation continues to advocate for improved standards in respiratory care. By participating in research, sharing lived experiences, and supporting advocacy campaigns, members of the public can help ensure that the patient perspective remains at the heart of medical policy. To stay informed on the latest developments, research, and expert insights, readers are encouraged to join the foundation’s mailing list to receive regular updates on these critical healthcare initiatives.
